Compare EVF & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVF | CALC |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | EVF | CALC |
|---|---|---|
| Price | $5.31 | $5.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 93.3K | ★ 96.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $1.42 |
| 52 Week High | $6.84 | $7.20 |
| Indicator | EVF | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 50.30 |
| Support Level | $5.25 | $5.05 |
| Resistance Level | $5.38 | $5.71 |
| Average True Range (ATR) | 0.04 | 0.70 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 36.60 | 16.74 |
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.